RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an 'Outperform' rating on Viracta Therapeutics (NASDAQ:VIRX) and maintained a $7 price target.
October 05, 2023 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an 'Outperform' rating on Viracta Therapeutics and maintained a $7 price target.
The reiteration of an 'Outperform' rating by a reputable analyst like Gregory Renza from RBC Capital is a positive signal for Viracta Therapeutics. The maintained price target of $7 also indicates confidence in the company's performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100